TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26307050

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic morphologically selected sperm injection (IMSI)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Conventional intracytoplasmic sperm injection (cICSI)
Number of subjects: 121
Study: 23810874

Group type: EXPERIMENTAL
Intervention: Intensified group treated with RAS antagonists and beta-blockers
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Intensified group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 300
Study: 21184869

Group type: EXPERIMENTAL
Intervention: Propofol plus fentanyl (0.25 mg/kg plus 50 μg intravenously)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Midazolam plus fentanyl (0.05 mg/kg plus 50 μg intravenously)
Number of subjects: 210
Study: 20149045

Group type: EXPERIMENTAL
Intervention: Very low dose oral contraceptives (100 microg levonorgestrel + 20 microg ethinyl estradiol)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Low dose oral contraceptives (150 microg desogestrel + 30 microg ethinyl estradiol)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Very low dose oral contraceptives
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Low dose oral contraceptives
Number of subjects: 186
Study: 17530986

Group type: EXPERIMENTAL
Intervention: CHO-PRO supplement (6.2% carbohydrate and 1.5% protein)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (electrolyte and artificial sweetener beverage)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CHO-PRO supplement
Number of subjects: 34
Study: 16488469

Group type: EXPERIMENTAL
Intervention: Standardized educational leaflets and post-discharge telephone counseling regarding fall prevention strategies
Number of subjects: 102

Group type: COMPARATOR
Intervention: Attention-controls
Number of subjects: 102
Study: 12556774

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy
Number of subjects: 282

Group type: COMPARATOR
Intervention: Endoscopic papillary balloon dilatation
Number of subjects: 282
Study: 10516536

Group type: EXPERIMENTAL
Intervention: Mediterranean-style restricted diet
Number of subjects: 16
Study: 8542862

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.5% end‐tidal, 0.73 MAC) with N2O 58% (0.58 MAC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Enflurane (1.2% end‐tidal, 0.7 MAC) with N2O 57% (0.57 MAC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both sevoflurane and enflurane
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia
Number of subjects: 80
Study: 1773716

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (INI) 1 U/kg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 6923833

Group type: EXPERIMENTAL
Intervention: Prophylaxis with mezlocillin and oxacillin (4 and 2 grams) every 8 hours, starting after intubation.
Number of subjects: 297

Group type: COMPARATOR
Intervention: Control group (no prophylaxis).
Number of subjects: 297
Study: 30455187

Group type: EXPERIMENTAL
Intervention: MDMA (100 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MDMA
Number of subjects: 20
Study: 28606620

Group type: EXPERIMENTAL
Intervention: Lumacaftor and ivacaftor (200 mg lumacaftor and 250 mg ivacaftor every 12 hours for 24 weeks)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Lumacaftor and ivacaftor
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 25809853

Group type: EXPERIMENTAL
Intervention: Low-fat spread with added plant sterols (3 g/d)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (low-fat spread without added plant sterols)
Number of subjects: 240
Study: 23274956

Group type: COMPARATOR
Intervention: 3 months of prednisolone followed by 3 months of placebo (n=74)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 6 months of prednisolone (n=76)
Number of subjects: 150
Study: 22232847

Group type: EXPERIMENTAL
Intervention: Test formulation of digoxin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference formulation of digoxin
Number of subjects: 20
Study: 19695711

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 126

Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 126
Study: 16892797

Group type: EXPERIMENTAL
Intervention: Dynamic hip screw (DHS, group A, n=42)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Anatomical proximal femur bone plate (group B, n=23)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Proximal femoral nail (PFN, group C, n=8)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Dynamic condylar screw (DCS, group D, n=15)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 88
Study: 12942977

Group type: EXPERIMENTAL
Intervention: Complex tones in cosine phase (CPH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex tones in random phase (RPH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gaussian noise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPH tone as forward masker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RPH tone as forward masker
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noise as forward masker
Number of subjects: 0
Study: 10631214

Group type: COMPARATOR
Intervention: Placebo inhaler bid + bolus placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formoterol Turbuhaler 24 microg metered dosage bid (delivered dosage 18 microg bid) + placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg bid + bolus IV hydrocortisone, 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg bid + bolus inhaled budesonide, 1,600 microg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formoterol alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formoterol + hydrocortisone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formoterol + budesonide
Number of subjects: 12
Study: 9021907

Group type: EXPERIMENTAL
Intervention: MgSO4 infusion
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no treatment or digoxin for specific cases)
Number of subjects: 200
Study: 1411622

Group type: EXPERIMENTAL
Intervention: Carboplatin (starting dose of 320 mg/m2)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide/carboplatin
Number of subjects: 418

Group type: COMPARATOR
Intervention: Cyclophosphamide/cisplatin
Number of subjects: 418
Study: 6093240

Group type: EXPERIMENTAL
Intervention: Cefotaxime (short course)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control (no antibiotics)
Number of subjects: 179
Study: 29368545

Group type: EXPERIMENTAL
Intervention: Walking (10 minutes)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Meditation (10 minutes)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Walking then Meditation (10 minutes each)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Meditation then Walking (10 minutes each)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Sitting (inactive control)
Number of subjects: 110
Study: 30122326

Group type: EXPERIMENTAL
Intervention: Additional yoga breathing with intermittent breath holding for 20 minutes, 8 weeks duration
Number of subjects: 116

Group type: COMPARATOR
Intervention: Regular yoga practice (control group)
Number of subjects: 116
Study: 27470232

Group type: EXPERIMENTAL
Intervention: Inhaled milrinone (iMil)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 25267274

Group type: EXPERIMENTAL
Intervention: Primary prevention ICD patients with EPS (group 1)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Primary prevention ICD patients without EPS (group 2)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Secondary prevention ICD patients (group 3)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Secondary prevention ICD patients with positive EPS result
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Secondary prevention ICD patients with negative EPS result
Number of subjects: 470

Group type: COMPARATOR
Intervention: EPS-guided primary prevention ICD patients
Number of subjects: 470
Study: 22196566

Group type: EXPERIMENTAL
Intervention: 5 weekly 30-min massages
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 10 weekly 30-min massages
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no massage therapy)
Number of subjects: 50
Study: 20143202

Group type: EXPERIMENTAL
Intervention: Humor therapy group (experimental group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no specific treatment)
Number of subjects: 90
Study: 18056902

Group type: EXPERIMENTAL
Intervention: Amoxicillin (500 mg 3 times per day for 7 days)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Topical Budesonide (200 mug in each nostril once per day for 10 days)
Number of subjects: 240

Group type: COMPARATOR
Intervention: No Amoxicillin (placebo)
Number of subjects: 240

Group type: COMPARATOR
Intervention: No Budesonide (placebo)
Number of subjects: 240
Study: 16086559

Group type: EXPERIMENTAL
Intervention: PTCA with provisional stenting (n = 109)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Stent (n = 111)
Number of subjects: 220
Study: 11152035

Group type: EXPERIMENTAL
Intervention: Myopexy (Faden)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-Faden surgery
Number of subjects: 120
Study: 9506495

Group type: EXPERIMENTAL
Intervention: Video self-instruction (VSI) training program for adult CPR
Number of subjects: 89

Group type: COMPARATOR
Intervention: Traditional CPR training (American Heart Association Heartsaver course)
Number of subjects: 89
Study: 7827843

Group type: EXPERIMENTAL
Intervention: Desmopressin 20 micrograms intranasal at night
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 3044425

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31862159

Group type: EXPERIMENTAL
Intervention: Hypnosis technique
Number of subjects: 272

Group type: COMPARATOR
Intervention: Nocebo group
Number of subjects: 272

Group type: COMPARATOR
Intervention: Neutral group
Number of subjects: 272
Study: 30261839

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1 mg/kg intravenous bolus before anesthetic induction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 40
Study: 28684372

Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI) 1320 cGy, cyclophosphamide 120 mg/kg, and fludarabine 75 mg/m2 (TCF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nontrial TCF regimen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nontrial TBI-containing regimens
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nontrial chemotherapy-only regimens
Number of subjects: 100
Study: 26678630

Group type: EXPERIMENTAL
Intervention: Perindopril/β-blocker
Number of subjects: 7534

Group type: COMPARATOR
Intervention: Placebo/β-blocker
Number of subjects: 7534
Study: 23076845

Group type: EXPERIMENTAL
Intervention: Oxandrolone 0.03 mg/kg per day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Oxandrolone 0.06 mg/kg per day
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 21550084

Group type: COMPARATOR
Intervention: Resting energy expenditure (REE) in COPD patients
Number of subjects: 14

Group type: COMPARATOR
Intervention: Endogenous leucine flux in COPD patients
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nonoxidative leucine disposal in COPD patients
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Correlation between REE and endogenous leucine flux
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Correlation between REE and nonoxidative leucine disposal
Number of subjects: 14

Group type: COMPARATOR
Intervention: Plasma concentrations of inflammatory markers (C-reactive protein and interleukin-6)
Number of subjects: 14
Study: 18355325

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg once daily
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 16542769

Group type: EXPERIMENTAL
Intervention: Phytosterol-ester enriched spreads
Number of subjects: 0
Study: 14978854

Group type: EXPERIMENTAL
Intervention: Ximelagatran (36 mg twice daily)
Number of subjects: 7399

Group type: COMPARATOR
Intervention: Warfarin (INR = 2-3)
Number of subjects: 7399
Study: 10563455

Group type: EXPERIMENTAL
Intervention: Chronic psychosis patients with parasuicide
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Chronic psychosis patients who are attempters
Number of subjects: 704

Group type: COMPARATOR
Intervention: Chronic psychosis patients who are nonattempters
Number of subjects: 704
Study: 8695563

Group type: EXPERIMENTAL
Intervention: Prophylactic surfactant treatment
Number of subjects: 304

Group type: COMPARATOR
Intervention: Rescue surfactant treatment
Number of subjects: 304
Study: 1811815

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms qid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dalargin (1 mg bid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dalargin
Number of subjects: 0
Study: 6133544

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 20 mg temazepam
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 28658181

Group type: EXPERIMENTAL
Intervention: Autologous auricular cartilage
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Bovine acellular dermal matrix (Surgimend)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Porcine acellular dermal matrix (Enduragen)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Auricular cartilage
Number of subjects: 49
Study: 27225607

Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine (group P, n=80)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Combination of 2-propanol and benzalkonium chloride (group B)
Number of subjects: 160
Study: 25414318

Group type: EXPERIMENTAL
Intervention: Renal rehabilitation exercise program (usual care plus guided exercise two times per week for 12 weeks, 24 sessions)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 107
Study: 22509084

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg od
Number of subjects: 114

Group type: COMPARATOR
Intervention: Famotidine 10 mg bid plus mosapride 5 mg tid
Number of subjects: 114
Study: 20132023

Group type: EXPERIMENTAL
Intervention: Zuspan's scheme (1 g/h by continuous intravenous infusion)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Alternative scheme (2 g in bolus every two hours)
Number of subjects: 29
Study: 18386570

Group type: EXPERIMENTAL
Intervention: Quxie Capsule (QXC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine treatment for cancer (chemotherapy and radiotherapy)
Number of subjects: 40
Study: 15607319

Group type: COMPARATOR
Intervention: Calcitonin (200 IU/day)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Alendronate (10 mg/day)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 12709796

Group type: EXPERIMENTAL
Intervention: Alveofact (SA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poractant (SB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beractant (SC)
Number of subjects: 0
Study: 10349523

Group type: EXPERIMENTAL
Intervention: Ceftibuten (10 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftibuten (15 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftibuten (20 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythromycin-sulfisoxazole (14 days)
Number of subjects: 0
Study: 8698872

Group type: EXPERIMENTAL
Intervention: Intraarticular morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Opioids expressed in inflamed tissue
Number of subjects: 0
Study: 1960241

Group type: EXPERIMENTAL
Intervention: Plax pre-brushing rinse, 15 ml, rinsed twice daily for 30 seconds
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo rinse, 15 ml, rinsed twice daily for 30 seconds
Number of subjects: 10
Study: 7346744

Group type: EXPERIMENTAL
Intervention: Indomethacin (IN) 0.25 mg/kg orally for two doses, 24 hours apart
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 6381166

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg b.i.d.
Number of subjects: 32
Study: 29040812

Group type: EXPERIMENTAL
Intervention: Snacks made from buckwheat (32 g serving; 141 kcal)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pita bread made from buckwheat flour (50 g serving; 135 kcal)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Reference snack products made from corn or rice flour
Number of subjects: 38

Group type: COMPARATOR
Intervention: Water (no-kilocalorie control)
Number of subjects: 38
Study: 27081016

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 312

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg
Number of subjects: 312
Study: 23877541

Group type: EXPERIMENTAL
Intervention: keepin' it REAL prevention program
Number of subjects: 432

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 432
Study: 22951192

Group type: EXPERIMENTAL
Intervention: Abdominoperineal extralevator resection (APER)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard abdominoperineal resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extralevator abdominoperineal resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional and quality-of-life-related outcomes
Number of subjects: 0
Study: 19397753

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) administered for 4 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo administered for 4 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: CMA patients vs. atopic eczema only
Number of subjects: 35
Study: 17977469

Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (2, 4, or 6 g/d, 26% DHA, 6% EPA)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (Sunola oil)
Number of subjects: 67
Study: 16122456

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no aprotinin)
Number of subjects: 33
Study: 12351377

Group type: EXPERIMENTAL
Intervention: CEBPA mutations
Number of subjects: 135

Group type: COMPARATOR
Intervention: No CEBPA mutations
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: FLT3-ITD
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Intermediate cytogenetic risk subgroup with CEBPA mutations
Number of subjects: 135
Study: 10482212

Group type: EXPERIMENTAL
Intervention: Parental presence during procedures
Number of subjects: 16
Study: 8944401

Group type: EXPERIMENTAL
Intervention: 40 mg IV cocaine hydrochloride
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 2006595

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine and Lidocaine
Number of subjects: 0
Study: 6963328

Group type: EXPERIMENTAL
Intervention: moroxydine chloride (0.04 g/kg a day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: no specific treatment (control)
Number of subjects: 49
Study: 29945851

Group type: EXPERIMENTAL
Intervention: Veggie Van (VV) mobile produce market intervention
Number of subjects: 201
Study: 28485312

Group type: EXPERIMENTAL
Intervention: Continuous infusion of meropenem (loading dose of 0.5 g followed by 3 g/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intermittent administration of meropenem (initial dose of 1.5 g followed by 1 g every 8 hours)
Number of subjects: 50
Study: 25141779

Group type: EXPERIMENTAL
Intervention: Integrated care group
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 178
Study: 24089227

Group type: EXPERIMENTAL
Intervention: Microbiological and immunological enteral nutrition (MEIN)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Ordinary enteral nutrition liquid (EN)
Number of subjects: 56
Study: 22379906

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60

Group type: COMPARATOR
Intervention: TIVA
Number of subjects: 60
Study: 19531697

Group type: EXPERIMENTAL
Intervention: Perioperative β-blocker use
Number of subjects: 10183

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10183
Study: 16855407

Group type: EXPERIMENTAL
Intervention: H. pylori infection assessment using C‐urea breath test and anti‐H. pylori IgG antibody titers
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Treatment of H. pylori infection
Number of subjects: 60
Study: 12874393

Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine (3,4-DAP) 20 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 11738037

Group type: EXPERIMENTAL
Intervention: Greater activity in the left fusiform face area (FFA) and left dorsolateral prefrontal cortex (DLPFC) when probe faces matched the remembered face.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activity in the anterior cingulate cortex (ACC) when probe faces did not match the remembered face.
Number of subjects: 0
Study: 9215513

Group type: EXPERIMENTAL
Intervention: Full intervention (cholesterol screening and dietary education)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Partial intervention (dietary education only)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Control (no cholesterol screening, only dietary education)
Number of subjects: 635
Study: 8205303

Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (100 mg/day)
Number of subjects: 0
Study: 3300570

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31228031

Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (MAS) 12.5-75 mg
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280